A number of new agreements have been signed between Apollon Formularies and Jamaica’s Cannabis License Authority (CLA) licensed cultivators allowing access to high-quality flower.
Apollon has signed more than a dozen tripartite agreements with Jamaica’s CLA which will enable the company to use high-quality cannabis flower to accelerate processing and manufacturing. The medical cannabis products will be used for patients, clinical trials and export.
The company has also established the Apollon Kannabiz Cooperative which aims to ensure that Jamaica’s cannabis growers are not left out of the regulated medical cannabis system, allowing traditional farmers to move into the legal industry.
The company has stated it believes that the local farmers should not only “grow for us” but should also be given an opportunity to “grow with us”.
Jamaica’s Minister of State in the Ministry of Industry, Commerce, Agriculture and Fisheries, Hon. Floyd Green, hailed the initiative at the official opening in Westmoreland, Jamaica, in October 2019: “Apollon is, indeed, cognisant of the need to develop a holistic sector, which does not overlook the traditional farmers.
“Indeed, let us allow our farmers to not just grow for the sector but to also grow with the sector in a meaningful and sustainable way.”
CLA director of enforcement and monitoring, Faith Graham, speaking at a recent Jamaica Information Service (JIS) think tank, commented: “By insisting on a standard for our licence holders and those interested in becoming a part of our local market, we are showing that we operate at an international level as we apply best practices for the global industry.
“The CLA operates a closed-loop system, characterised by a tripartite agreement that is fundamental to the industry maintaining its integrity. The tripartite agreement ensures that the ganja (cannabis) that is cultivated is sold to another licensee.”
Apollon Formularies Jamaica Limited CEO, Paul Burke, commented: “Apollon‘s goal is to reposition Jamaica’s medical cannabis industry, in terms of science, research and development, product manufacturing, affordable patient care, and legal export, while becoming an industry leader in the global pharmaceutical and nutraceutical medical cannabis space.”
“We are pleased that so many CLA-Licensed cultivators have signed tripartite agreements with the company indicating their interest and willingness to grow and provide substantial quantities of high-quality, freshly harvested cannabis buds to be used by Apollon to process and manufacture large quantities of medical cannabis products which will significantly accelerate and increase our inventory for patients, clinical trials, and export,” added Stephen Barnhill, MD, CEO of Apollon Formularies.
“We also recognise and appreciate the experience and dedication of traditional Jamaican ganja farmers and look forward to expanding the Apollon Kannabiz Cooperative to provide jobs and income to help local farmers have a better way of life for themselves and their families.”
Biologists identify “hacks” cannabis uses to make cannabinoids
The research provides insight into how trichomes create high quantities of cannabinoids without the plant poisoning itself.
Previously, it was unknown how cannabis naturally creates high quantities of cannabinoids and terpenes. Now, new research from biologists at the University of British Colombia has defined the “high efficiency” hacks that the plant’s cells use to do this.
A number of biotechnology companies are now using yeast or cell cultures to create synthetic cannabinoids. The process allows for the mass production of cannabinoids to create a high volume of products in order to keep up with consumer demand.
In a new study, published in the journal Current Biology, plant biologists uncovered the microenvironments in which THC is produced and transported in cannabis trichomes, shedding light on several critical points in the pathway of making THC or CBD within the cell.
University of British Columbia botanist who led the research, Dr Sam Livingston, commented” “This really helps us understand how the cells in cannabis trichomes can pump out massive quantities of tetrahydrocannabinol (THC) and terpenes—compounds that are toxic to the plant cells at high quantities – without poisoning itself.
“This new model can inform synthetic biology approaches for cannabinoid production in yeast, which is used routinely in biotechnology.
“Without these ‘tricks’ they’ll never get efficient production.”
Livingston, along with co-author Dr Lacey Samuels, used rapid freezing of cannabis glandular trichomes to immobilise the plant’s cellular structures and the metabolites in situ.
This enabled them to investigate cannabis glandular trichomes using electron microscopes that revealed cell structure at the nano level, showing that the metabolically active cells in cannabis form a “supercell” that acts as a tiny metabolic biofactory.
Until now, synthetic biology approaches have focused on optimising the enzymes responsible for making THC and CBD – like building a factory with the most efficient machinery to make as much product as possible. However, these approaches haven’t developed an efficient way to move intermediate substances from one enzyme to another, or from inside the cell to the outside of the cell where final products can be collected.
This research helps to define the subcellular “shipping routes” that cannabis uses to create an efficient pipeline from raw materials to end products without accumulating toxins or waste products.
Dr Samuels stated: “For more than 40 years, everything that we thought about cannabis cells was inaccurate because it was based on dated electron microscopy.”
“This work defines how cannabis cells make their product. It’s a paradigm shift after many years, producing a new view of cannabinoid production. This work has been challenging, partly the result of legal prohibition and also due to the fact that no protocol for the genetic transformation of cannabis has been published.”
New partnership to commercialise synthetic THCV and rare cannabinoids
Open Book Extracts has partnered with developers of a proprietary chemical synthesis platform that produces ultra-pure, high quality, sustainable cannabinoids, Nalu Bio.
Open Book Extracts (OBX) has entered into a research, development and commercialisation partnership with Nalu Bio.
The partnership will allow Nalu Bio to advance its THCV production method from research and development to commercial-scale manufacturing using its proprietary and scalable synthesis platform.
With a 76,000 sf. NSF- and ISO 9001-certified research and production facility near Durham, North Carolina, OBX and Nalu Bio plan to begin initial production of THCV in September 2022 with market-ready compounds available before the end of the year.
CTO of Nalu Bio, Matthew Roberts, commented: “Our THCV is produced in highly scalable reactors at factory-scale, using low-cost, safe and effective starting materials. Nalu Bio and OBX are both innovators in their respective fields, and this partnership is mutually beneficial for two industry leaders.
“Nalu Bio prides itself on partnering excellence, and we’re excited to deliver high-quality, safe, and low-cost cannabinoid ingredients and products to the market.”
Nalu Bio’s vision for the synthesis and cost-effective mass production of cannabinoids mimics the history of aspirin – the therapeutic value of aspirin for pain relief was discovered, and while initially derived from willow bark, it is now mass produced at factory-scale with higher quality and dosage consistency, which has benefited billions of consumers worldwide as it has become the most commonly used drug in the world.
THCV will be the first cannabinoid available at commercial scale through this partnership, allowing OBX and Nalu Bio to offer the highest quality, most consistent dosage of THCV.
Both OBX and Nalu Bio envision a range of additional cannabinoids to be released through this partnership,including a broad range of cannabinoids from hemp and natural sources, such as CBD, CBN, CBC, CBG, CBT, CBDa, CBGa, CBDV, and THCV.
OBX CEO, Dave Neundorfer, commented: “I am excited about the value Nalu Bio and OBX will bring to the cannabinoid therapeutics market. This partnership is well-positioned to meet the needs of the growing synthetic cannabinoid market and deliver potentially life-changing products to consumers worldwide.”
Greece welcomes first medical cannabis plants from Israel
Mother plants have arrived in Greece, marking the beginning of production for Tikun Europe.
Tikun Europe has welcomed the first mother plants from Israel and will now begin cultivation in the company’s facility at Korinthos, Greece.
Transportation of the plants was carried out by Skyserv Ground Handling Services. The shipment of the plants was made in specially designed containers under controlled environment ensuring the best possible conditions throughout the transportation from Israel to their final destination.
Cultivation will take place in Tikun Europe’s vertically integrated greenhouse unit, with an area of 21,000 m 2 and it anticipates an annual production capacity of 10 tonnes of dry flower.
CEO of Tikun Europe, Nikos Beis, said: “We welcome the first mother plants to our facilities in Greece. Their arrival marks the beginning of production at the factory in Korinthos, which takes us one step closer to the realisation of our commitment.
“Our factory, being the largest pharmaceutical facility in its industry in Europe, is committed to creating innovative, high-quality medical cannabis products.
“A new era is beginning for our country with the operation of our Tikun Europe facility, paving the way for Greece to become one of the main players in the field of production and export of medical cannabis products.”
The plants will be used for propagation under strict protocols that will ensure the preservation of the unique characteristics of the mother plants to the future generations. The facility is expected to reach its full capacity levels gradually in the near future, to deliver a wide variety of finished medical cannabis dosage forms.
The company’s greenhouse and production units are designed to comply with the GACP/EU-GMP standards, and it holds all the necessary licenses and certifications in order for its operation.
COO and vice president of the board of Tikun Europe, Dimitris Giannopoulos, stated: “After completing the construction of our production facility in Korinthos, today signifies another important milestone, that brings us one step closer to the beginning of cultivation of medical cannabis plants in the country.
“The main challenge and opportunity now become the development and production of a complete portfolio of high quality finished medical cannabis products to meet the needs of patients in Greece and in Europe”.
Commercial director of Skyserv Ground Handling Services, Martha Georgila, stated: “We are very happy that Tikun Europe trusted Skyserv to implement the first transport of mother plants in Greece.
“Following all transportation protocols for that type of merchandises, along with the specific storage conditions that were required during their stay at the airport area, we managed to keep them intact until their departure to the company’s factory in Korinthos.”